BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives DOI Open Access
S. Cedrés, Augusto Valdivia,

Ilaria Priano

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(9), P. 1581 - 1581

Published: May 6, 2025

Pleural mesothelioma (PM) is a locally aggressive tumor associated with asbestos exposure. Despite legislative efforts to regulate use, its incidence continues rise in some parts of the world. Chemotherapy and immunotherapy have improved survival PM patients, but overall remains poor. Molecular analysis patients has shown that most alterations occur suppressor genes, BAP1 being frequently affected. Patients germline mutations been reported better prognosis, this not observed those somatic mutations. Interest developing drugs targeting loss led several phase II studies recent years. Unfortunately, initial results very promising. In review, we conclude that, at time, contradictory from limited number evaluated, BAP1, commonly altered gene PM, yet suitable for use clinical practice as prognostic or predictive factor. Future are needed establish value BAP1.

Language: Английский

Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights DOI
Hedy L. Kindler, Ibiayi Dagogo‐Jack, Marc de Perrot

et al.

JCO Oncology Practice, Journal Year: 2025, Volume and Issue: unknown

Published: March 7, 2025

Language: Английский

Citations

1
A Meta-Analysis of First-Line Treatments for Unresectable Pleural Mesothelioma: Indirect Comparisons from Reconstructed Individual Patient Data of Six Randomized Controlled Trials DOI Open Access
Andrea Messori, Sabrina Trippoli, Eugenia Piragine

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(3), P. 503 - 503

Published: Feb. 3, 2025

Background: In unresectable pleural mesothelioma, pemetrexed+cisplatin as first line is considered the standard of care, but novel treatments have been recently proposed. Methods: Our objective was to compare, albeit indirectly, results randomized controlled trials on overall survival (OS). The IPDfromKM method employed for reconstruct individual patient data (IPD) from graphs Kaplan–Meier curves. Cox statistics run estimate hazard ratios (HRs). Results: After a literature search Medline (via PubMed) and Scopus databases, six were identified in which five new (nivolumab plus ipilimumab, bevacizumab pemetrexed cisplatin, chemotherapy pembrolizumab, ONCOS-102 cisplatin/carboplatin cediranib with maintenance cediranib) evaluated. trials, cisplatin care given control arms. Nivolumab pembrolizumab showed significantly better OS compared controls. did not improve OS. contrast, worsened alone cediranib. Discussion: analysis indicates that, patients three provided significant benefit care. Further research needed confirm found our some treatments, whereas do seem deserve further research.

Language: Английский

Citations

0
Why the MARS2 Trial Does Not Mean the End of All Mesothelioma Surgery DOI Open Access
David Waller,

Rocco Bilancia,

Luigi Ventura

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 724 - 724

Published: Feb. 21, 2025

Background/Objectives: The published report of the MARS2 trial suggested that addition extended pleurectomy/decortication to chemotherapy for pleural mesothelioma was harmful. Thus, goes on, all disease should be considered as unresectable and no further surgery survival benefit considered. This statement has changed clinical practice in UK; however, design several limitations which prevent its conclusions being over interpreted. These include following: inclusion too many patients who would fall outside contemporary selection criteria including age, co-morbidity histology; unnecessary resection much tissue, particularly diaphragm, operating on late process due less than rigorous staging. Methods: We retrospectively analysed outcome data 79 158 (50%) underwent surgical arm study were operated by authors four five centres. revised staging these applying forthcoming 9th TNM edition measurement thickness. Results: Based reported guidelines, reset stage I or II epithelioid PM. found 52 (66%) (group A) not have been using following reasons: non-epithelioid PM 5; cT/4 35; cT2N1 10 2 cT2N0 (pN1), detected preoperative mediastinal biopsy. Of 27 (34%) fulfilling current B), 12 cT1N0, 1 cT1N1, 6 cT1N0pN1 8 cT2N0, with median group B 32 (1–72) months, significantly higher A: 8.5 (1–55) p < 0.0005 (Mann–Whitney). Conclusions: As applied MARS2, cannot universally those Together favourable postoperative this selected group, we suggest there is still scope a early-stage mesothelioma.

Language: Английский

Citations

0
BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives DOI Open Access
S. Cedrés, Augusto Valdivia,

Ilaria Priano

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(9), P. 1581 - 1581

Published: May 6, 2025

Pleural mesothelioma (PM) is a locally aggressive tumor associated with asbestos exposure. Despite legislative efforts to regulate use, its incidence continues rise in some parts of the world. Chemotherapy and immunotherapy have improved survival PM patients, but overall remains poor. Molecular analysis patients has shown that most alterations occur suppressor genes, BAP1 being frequently affected. Patients germline mutations been reported better prognosis, this not observed those somatic mutations. Interest developing drugs targeting loss led several phase II studies recent years. Unfortunately, initial results very promising. In review, we conclude that, at time, contradictory from limited number evaluated, BAP1, commonly altered gene PM, yet suitable for use clinical practice as prognostic or predictive factor. Future are needed establish value BAP1.

Language: Английский

Citations

0